Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other.

Obesity is becoming one of healthcare's biggest long-term challenges, and treating it is creating one of the pharmaceutical industry's biggest opportunities. For many patients, managing weight goes beyond diet and exercise. Obesity is a chronic disease, and as treatment options improve, medicines are becoming an increasingly important part of how it is managed.

That puts Eli Lilly (LLY) and Novo Nordisk (NVO) in an interesting position. Both have built major businesses around diabetes and obesity, and both are pushing to stay ahead as demand for these treatments grows.

For dividend investors, however, the decision goes beyond which drug is better. Lilly offers stronger growth, while Novo offers a cheaper valuation and a higher dividend yield.

That makes this matchup particularly interesting. So which one offers the better balance of growth, value, and income today?

Eli Lilly and Company is a long-established pharmaceutical company best known for developing diabetes treatments. What many miss is that its portfolio covers a broader range of serious and chronic conditions, giving Lilly a diversified business.

It is the Goliath in this comparison, with a market cap of nearly $1.1 trillion.

Novo Nordisk A/S is a Danish pharmaceutical company with a century-long history in diabetes care. Much like Lilly, Novo has diabetes at the heart of its business, although it has also expanded into obesity and other chronic diseases.

In terms of size, Novo is clearly the smaller challenger, with a market cap of about $201 billion.

That size difference is hard to ignore, but it does not tell the whole story. In obesity, these two companies are fighting for many of the same patients, putting them on much more even ground than their market caps suggest.

The Race for the Next Big Obesity Treatment

Lilly and Novo Nordisk compete across several areas of medicine, but obesity is what makes this matchup particularly interesting. Both companies already have major treatments on the market, and neither appears willing to give up ground.

Lilly has Zepbound (Tirzepatide), while Novo Nordisk has Wegovy, putting the two companies head-to-head in the weight-loss market. But the rivalry is now moving into the realm of pills.

Novo launched the Wegovy pill in the U.S. in January, and it surpassed 3 million prescriptions in its first five months, indicating strong early demand.